iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 11/07/2025

9) Another caveat is that the treatment response was equally big in the 2015 Rituximab trial where physical functioning (Sf-36) increased from 40 to 68 (+28) The later randomised trial however showed no significant effect, which may also be the case here.

150

ME/CFS Science @mecfsscience.org · 11/07/2025

10) Luckily the authors have already started a randomized, double-blind and placebo-controlled study including patients with moderate to severe ME/CFS. This will hopefully provide more clarity. Link to the study: www.frontiersin.org/...

frontiersin.org

Frontiers | Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study

BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent...

271

ME/CFS research @cfsresearch.bsky.social · 11/07/2025

Looks like the placebo effect. They say 60% had marked improvement. If you look at their previous open-label rituximab trial (journals.plos.org/plosone/arti...), 64% had clinically significant responses, but there was no difference in the later placebo controlled trial.

journals.plos.org

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

Background Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We previously reported a pilot case series followed by a small, randomized, placebo-controlled pha...

000

Tom Kindlon @tomkindlon.bsky.social · 11/07/2025

@unroll.skywriter.blue unroll

100